The STOP-HF study used a BNP-guided strategy to further investigate and manage subclinical LVD in asymptomatic people aged over 40 years with at least 1 risk factor for HF (only 20% had T2DM) [5]. This evidence concerns the gene NPPB and type 2 diabetes mellitus.